GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Colorectal Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Renal Cell Carcinoma|Gastric Cancer|Pancreatic Cancer|Urothelial Cancer
Interventions: BIOLOGICAL: GEN1029 (HexaBody®-DR5/DR5)
Sponsor: Genmab